Jennifer Dahne
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jennifer Dahne has a total of 160 co-authors. Here are the top co-authors by number of shared publications:
- Carl. W. Lejuez
University of Kansas
15 shared publications Matthew J. Carpenter
Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston
10 shared publicationsAmy E. Wahlquist
East Tennessee State University
8 shared publicationsJacob Kustanowitz
Chevy Chase
7 shared publications- Matthew J. Carpenter
Department of Psychiatry and Behavioral Sciences Medical University of South Carolina Charleston SC USA
6 shared publications Vanessa A. Diaz
Department of Family Medicine, Medical University of South Carolina, Charleston
6 shared publications
Latest Publications
- 1 May 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 22 (5) , 735-741
Characterizing Survivors Living With Likely Incurable Cancer: A Closer Look at an Emerging Population
The number of individuals living with advanced and metastatic cancer that is likely incurable is rapidly growing. These individuals, treated with the intent to prolong life and maximize the quality of life, often experience cancer as a chronic disease and undergo treatment with multiple lines of therapy. Because of their experience with cancer as a chronic disease, this subgroup of survivors has unique survivorship challenges and corresponding needs. In recognition of this consideration, the Multinational Association of Supportive Care in Cancer and ASCO published standards and practice recommendations relevant to the delivery of quality survivorship care for this emerging population. As nascent research, clinical, and policy efforts focused on individuals living with advanced and metastatic cancer have expanded, a corresponding need to accurately and consistently define this population has emerged. To date, however, there is a lack of terminological clarity for this emerging survivor subgroup. To address the gap, this article discusses how the lack of clear, consistent definition of individuals living with advanced and metastatic cancer that is likely incurable represents a critical barrier to advancing research and improving clinical care for these individuals. We explore situations in which stage (advanced or metastatic) and treatment intent (curative vs noncurative) diverge. We propose that the essential characteristic that defines this survivor subgroup and differentiates them from individuals in other phases of survivorship is that they undergo noncurative treatment with the goal of prolonging life and improving quality of life, regardless of the anatomic stage. Finally, we discuss emerging strategies to identify individuals living with likely incurable cancer from the electronic health record and cancer registries for the purposes of research and clinical care.
- 1 May 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 22 (5) , 735-741
Characterizing Survivors Living With Likely Incurable Cancer: A Closer Look at an Emerging Population
The number of individuals living with advanced and metastatic cancer that is likely incurable is rapidly growing. These individuals, treated with the intent to prolong life and maximize the quality of life, often experience cancer as a chronic disease and undergo treatment with multiple lines of therapy. Because of their experience with cancer as a chronic disease, this subgroup of survivors has unique survivorship challenges and corresponding needs. In recognition of this consideration, the Multinational Association of Supportive Care in Cancer and ASCO published standards and practice recommendations relevant to the delivery of quality survivorship care for this emerging population. As nascent research, clinical, and policy efforts focused on individuals living with advanced and metastatic cancer have expanded, a corresponding need to accurately and consistently define this population has emerged. To date, however, there is a lack of terminological clarity for this emerging survivor subgroup. To address the gap, this article discusses how the lack of clear, consistent definition of individuals living with advanced and metastatic cancer that is likely incurable represents a critical barrier to advancing research and improving clinical care for these individuals. We explore situations in which stage (advanced or metastatic) and treatment intent (curative vs noncurative) diverge. We propose that the essential characteristic that defines this survivor subgroup and differentiates them from individuals in other phases of survivorship is that they undergo noncurative treatment with the goal of prolonging life and improving quality of life, regardless of the anatomic stage. Finally, we discuss emerging strategies to identify individuals living with likely incurable cancer from the electronic health record and cancer registries for the purposes of research and clinical care.
- Open Access
- 24 October 2025
- Published by Cambridge University Press (CUP) in Journal of Clinical and Translational Science
- Vol. 9 (1) , 1-19
Advancing translational science through trial integrity: REDCap-based approaches to mitigating fraud and bias
Decentralized clinical trials (DCTs) have the potential to increase pace and reach of recruitment as well as to improve sample representation, compared to traditional in-person clinical trials. However, concerns linger regarding data integrity in DCTs due to threats of fraud and sampling bias. The purpose of this report is to describe two tools that we have developed and successfully implemented to combat these threats. Cheatblocker and QuotaConfig are two external modules that we have made publicly available within the REDCap data capture system to target fraud and sampling bias, respectively. We describe the modules, present two case examples in which we used the modules successfully, and discuss the potential impact of tools such as these on data integrity in DCTs. We situate this discussion within the broader landscape of translational science wherein we strive to improve research rigor and efficiency to maximize public health benefit.
- 24 October 2025
- Published by Cambridge University Press (CUP) in Journal of Clinical and Translational Science
- Vol. 9 (1) , 1-19
Open AccessAdvancing translational science through trial integrity: REDCap-based approaches to mitigating fraud and bias
Decentralized clinical trials (DCTs) have the potential to increase pace and reach of recruitment as well as to improve sample representation, compared to traditional in-person clinical trials. However, concerns linger regarding data integrity in DCTs due to threats of fraud and sampling bias. The purpose of this report is to describe two tools that we have developed and successfully implemented to combat these threats. Cheatblocker and QuotaConfig are two external modules that we have made publicly available within the REDCap data capture system to target fraud and sampling bias, respectively. We describe the modules, present two case examples in which we used the modules successfully, and discuss the potential impact of tools such as these on data integrity in DCTs. We situate this discussion within the broader landscape of translational science wherein we strive to improve research rigor and efficiency to maximize public health benefit.
- Open Access
- 25 September 2025
- Published by Cambridge University Press (CUP) in Journal of Clinical and Translational Science
- Vol. 9 (1) , e230
Evaluation of a remote biomarker capture system integrated with REDCap: A decentralized randomized trial
Introduction: Decentralized clinical trials (DCTs) are often hindered by challenges in remotely capturing biomarkers. To address this gap, we developed MyTrials, a mobile application integrated with REDCap, designed to facilitate the remote capture of biomarkers via Bluetooth-enabled remote patient monitoring (RPM) devices. The purpose of the present study was to evaluate the feasibility and acceptability of MyTrials among participants within a DCT design. Methods: In this four-arm randomized trial, 47 participants were allocated to receive zero, one, two, or three RPM devices. Participants were asked to use their devices once per week for a total of four weeks to remotely provide biomarkers via MyTrials. Feasibility was assessed using objective metrics of successful biomarker submission (i.e., valid device data accompanied by a video confirming participant identity) alongside the participant-reported Feasibility of Intervention Measure (FIM). Acceptability was evaluated via the Acceptability of Intervention Measure (AIM) and the System Usability Scale (SUS). Results: Among participants assigned at least one device, the successful biomarker submission rate was 74% across all study weeks. FIM and AIM scores exceeded prespecified feasibility benchmarks across all conditions except the zero-device condition. SUS scores consistently indicated high usability across all conditions (range: 77.29–94.29). Conclusions: The MyTrials platform is a feasible and acceptable solution for remote biomarker capture in DCTs. These findings support the potential of MyTrials to advance remote data collection in clinical research.
- 25 September 2025
- Published by Cambridge University Press (CUP) in Journal of Clinical and Translational Science
- Vol. 9 (1) , e230
Open AccessEvaluation of a remote biomarker capture system integrated with REDCap: A decentralized randomized trial
Introduction: Decentralized clinical trials (DCTs) are often hindered by challenges in remotely capturing biomarkers. To address this gap, we developed MyTrials, a mobile application integrated with REDCap, designed to facilitate the remote capture of biomarkers via Bluetooth-enabled remote patient monitoring (RPM) devices. The purpose of the present study was to evaluate the feasibility and acceptability of MyTrials among participants within a DCT design. Methods: In this four-arm randomized trial, 47 participants were allocated to receive zero, one, two, or three RPM devices. Participants were asked to use their devices once per week for a total of four weeks to remotely provide biomarkers via MyTrials. Feasibility was assessed using objective metrics of successful biomarker submission (i.e., valid device data accompanied by a video confirming participant identity) alongside the participant-reported Feasibility of Intervention Measure (FIM). Acceptability was evaluated via the Acceptability of Intervention Measure (AIM) and the System Usability Scale (SUS). Results: Among participants assigned at least one device, the successful biomarker submission rate was 74% across all study weeks. FIM and AIM scores exceeded prespecified feasibility benchmarks across all conditions except the zero-device condition. SUS scores consistently indicated high usability across all conditions (range: 77.29–94.29). Conclusions: The MyTrials platform is a feasible and acceptable solution for remote biomarker capture in DCTs. These findings support the potential of MyTrials to advance remote data collection in clinical research.
- 1 June 2025
- Published by American Medical Association (AMA) in JAMA Internal Medicine
- Vol. 185 (6) , 692-701
A Digital Depression Treatment Program for Adults Treated in Primary Care
Importance: More than two-thirds of US adults who screen positive for depression in the primary care setting do not receive treatment. These adults need evidence-based and scalable interventions.Objective: To determine the effectiveness of Moodivate, a self-directed digital intervention for mental health, in treating depression symptoms among patients in the primary care setting.Design, Setting, and Participants: This 3-group decentralized randomized clinical trial recruited participants from September 22, 2021, to December 27, 2023, and completed data collection on March 29, 2024. Adult patients with at least moderate symptoms of depression on the Patient Health Questionnaire-9 (score ≥10) were enrolled from 22 primary care clinics in South Carolina.Interventions: Participants received Moodivate (a digital behavioral activation intervention), Moodivate with health care provider access to information on patient use of the digital behavioral activation intervention in the electronic health record (EHR), or usual care for depression.Main Outcomes and Measures: The primary outcome was a change in depression symptoms on the Beck Depression Inventory-II (BDI-II) over 12 weeks. Secondary outcomes included a clinically significant improvement in depression symptoms on the BDI-II (10-point decrease in score), depression remission on the BDI-II (score ≤13), digital behavioral activation intervention engagement, and primary care provider (a physician or other health care professional who is responsible for a patient’s primary care) use of the EHR features.Results: Among 649 participants, 495 (76%) were female and the mean (SD) age was 44.68 (15.22) years. Participants who received the digital behavioral activation intervention, with and without EHR integration, had significantly improved depression symptoms vs those who received usual care over 12 weeks (least squares mean change from baseline for Moodivate: −10.34; SE = 0.82; d = 0.98; Moodivate with EHR: −9.88; SE = 0.81; d = 0.93; usual care: −5.94; SE = −0.80; d = 0.54). Participants in the Moodivate groups had 2.5 to 3.0 times higher odds of having a clinically significant improvement in depression symptoms (Moodivate: OR, 2.98 [97.5% CI, 1.69-5.27]; P < .001; Moodivate with EHR: OR, 2.53 [97.5% CI, 1.45-4.41]; P < .001) and 2.3 to 2.6 times higher odds of experiencing depression remission (Moodivate: OR, 2.27 [97.5% CI, 1.16-4.44; P = .006; Moodivate with EHR: OR, 2.63 [97.5% CI, 1.38-5.04]; P < .001) than participants who received usual care. Participant engagement with Moodivate was high in the first month (68% to 100% weekly retention), and 33% of patients continued to use the digital behavioral activation intervention after 12 weeks. Fourteen percent of primary care providers who received access used the EHR functionality.Conclusions and Relevance: This randomized clinical trial found that a digital behavioral activation intervention is effective for treating adults with at least moderate symptoms of depression in the primary care setting.Trial Registration: ClinicalTrials.gov Identifier: NCT04463914
- 1 June 2025
- Published by American Medical Association (AMA) in JAMA Internal Medicine
- Vol. 185 (6) , 692-701
A Digital Depression Treatment Program for Adults Treated in Primary Care
Importance: More than two-thirds of US adults who screen positive for depression in the primary care setting do not receive treatment. These adults need evidence-based and scalable interventions.Objective: To determine the effectiveness of Moodivate, a self-directed digital intervention for mental health, in treating depression symptoms among patients in the primary care setting.Design, Setting, and Participants: This 3-group decentralized randomized clinical trial recruited participants from September 22, 2021, to December 27, 2023, and completed data collection on March 29, 2024. Adult patients with at least moderate symptoms of depression on the Patient Health Questionnaire-9 (score ≥10) were enrolled from 22 primary care clinics in South Carolina.Interventions: Participants received Moodivate (a digital behavioral activation intervention), Moodivate with health care provider access to information on patient use of the digital behavioral activation intervention in the electronic health record (EHR), or usual care for depression.Main Outcomes and Measures: The primary outcome was a change in depression symptoms on the Beck Depression Inventory-II (BDI-II) over 12 weeks. Secondary outcomes included a clinically significant improvement in depression symptoms on the BDI-II (10-point decrease in score), depression remission on the BDI-II (score ≤13), digital behavioral activation intervention engagement, and primary care provider (a physician or other health care professional who is responsible for a patient’s primary care) use of the EHR features.Results: Among 649 participants, 495 (76%) were female and the mean (SD) age was 44.68 (15.22) years. Participants who received the digital behavioral activation intervention, with and without EHR integration, had significantly improved depression symptoms vs those who received usual care over 12 weeks (least squares mean change from baseline for Moodivate: −10.34; SE = 0.82; d = 0.98; Moodivate with EHR: −9.88; SE = 0.81; d = 0.93; usual care: −5.94; SE = −0.80; d = 0.54). Participants in the Moodivate groups had 2.5 to 3.0 times higher odds of having a clinically significant improvement in depression symptoms (Moodivate: OR, 2.98 [97.5% CI, 1.69-5.27]; P < .001; Moodivate with EHR: OR, 2.53 [97.5% CI, 1.45-4.41]; P < .001) and 2.3 to 2.6 times higher odds of experiencing depression remission (Moodivate: OR, 2.27 [97.5% CI, 1.16-4.44; P = .006; Moodivate with EHR: OR, 2.63 [97.5% CI, 1.38-5.04]; P < .001) than participants who received usual care. Participant engagement with Moodivate was high in the first month (68% to 100% weekly retention), and 33% of patients continued to use the digital behavioral activation intervention after 12 weeks. Fourteen percent of primary care providers who received access used the EHR functionality.Conclusions and Relevance: This randomized clinical trial found that a digital behavioral activation intervention is effective for treating adults with at least moderate symptoms of depression in the primary care setting.Trial Registration: ClinicalTrials.gov Identifier: NCT04463914
- 10 December 2024
- Published by Oxford University Press (OUP) in Nicotine & Tobacco Research
- Vol. 27 (5) , 839-848
Can We Predict Who Will Experience Adverse Events While Using Smoking Cessation Pharmacotherapy? A Secondary Analysis of the EAGLES Clinical Trial
Introduction: Concerns about potential side effects remain a barrier to uptake of Food and Drug Administration-approved smoking cessation pharmacotherapy (ie, varenicline, bupropion, nicotine replacement therapy [NRT]). However, use of pharmacotherapy can double the odds of successful quitting. Knowledge of an individual’s likelihood of side effects while taking smoking cessation pharmacotherapy could influence treatment planning discussions and monitoring. Methods: We conducted a secondary, post hoc analysis to predict an individual’s likelihood of adverse events (AEs) using the Evaluating Adverse Events in a Global Smoking Cessation Study data from 4209 adults in the United States who smoked. Participants were randomized to receive 12 weeks of treatment with varenicline, bupropion, NRT patch, or placebo. Our models predicted the likelihood of moderate to severe psychiatric and nonpsychiatric AEs during treatment. Results: Using pretreatment demographic and clinical data, multivariable logistic regression models yielded acceptable areas under the receiver operating characteristic curve for an individual’s likelihood of moderate to severe (1) psychiatric AEs for bupropion and NRT and (2) nonpsychiatric AEs for varenicline and bupropion. Once we adjusted for demographic and baseline characteristics, medication was not associated with psychiatric AEs. Varenicline differed from placebo with regards to nonpsychiatric AEs. Conclusions: It is possible to predict person-specific likelihood of moderate to severe psychiatric and nonpsychiatric AEs during smoking cessation treatment, though the probability of psychiatric AEs did not differ by medication. Future work should consider factors related to implementation in clinical settings, including determining whether lower burden assessment protocols can be equally accurate for AE prediction. Implications: Using data from a large dataset people who smoke in the United States, it is possible to predict an individual’s likelihood of psychiatric and nonpsychiatric AEs during smoking cessation treatment prior to initiating treatment. These predictive models provide a starting point for future work addressing how best to modify and integrate such clinical decision support algorithms into treatment for smoking cessation.
- 10 December 2024
- Published by Oxford University Press (OUP) in Nicotine & Tobacco Research
- Vol. 27 (5) , 839-848
Can We Predict Who Will Experience Adverse Events While Using Smoking Cessation Pharmacotherapy? A Secondary Analysis of the EAGLES Clinical Trial
Introduction: Concerns about potential side effects remain a barrier to uptake of Food and Drug Administration-approved smoking cessation pharmacotherapy (ie, varenicline, bupropion, nicotine replacement therapy [NRT]). However, use of pharmacotherapy can double the odds of successful quitting. Knowledge of an individual’s likelihood of side effects while taking smoking cessation pharmacotherapy could influence treatment planning discussions and monitoring. Methods: We conducted a secondary, post hoc analysis to predict an individual’s likelihood of adverse events (AEs) using the Evaluating Adverse Events in a Global Smoking Cessation Study data from 4209 adults in the United States who smoked. Participants were randomized to receive 12 weeks of treatment with varenicline, bupropion, NRT patch, or placebo. Our models predicted the likelihood of moderate to severe psychiatric and nonpsychiatric AEs during treatment. Results: Using pretreatment demographic and clinical data, multivariable logistic regression models yielded acceptable areas under the receiver operating characteristic curve for an individual’s likelihood of moderate to severe (1) psychiatric AEs for bupropion and NRT and (2) nonpsychiatric AEs for varenicline and bupropion. Once we adjusted for demographic and baseline characteristics, medication was not associated with psychiatric AEs. Varenicline differed from placebo with regards to nonpsychiatric AEs. Conclusions: It is possible to predict person-specific likelihood of moderate to severe psychiatric and nonpsychiatric AEs during smoking cessation treatment, though the probability of psychiatric AEs did not differ by medication. Future work should consider factors related to implementation in clinical settings, including determining whether lower burden assessment protocols can be equally accurate for AE prediction. Implications: Using data from a large dataset people who smoke in the United States, it is possible to predict an individual’s likelihood of psychiatric and nonpsychiatric AEs during smoking cessation treatment prior to initiating treatment. These predictive models provide a starting point for future work addressing how best to modify and integrate such clinical decision support algorithms into treatment for smoking cessation.
- Open Access
- 28 August 2024
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 26, e52919
Expectations and Preferences for Digital Cessation Treatment: Multimethods Study Among Older Adults Who Smoke Cigarettes
Background: To address enduring age-related tobacco disparities, it is critical to promote cessation treatment among older adults (aged 65+ years). Digital health platforms offer opportunities for wide dissemination of evidence-based behavioral cessation support. However, existing digital cessation treatments are not tailored to unique aging-related needs and preferences, resulting in low uptake. Detailed information is needed about how to best adapt these treatments for this age group. Objective: We aimed to collect detailed, hypothesis-generating information about expectations and preferences for cessation digital treatment among older adults who smoke cigarettes. Methods: Semistructured interviews were conducted with adults aged 65+ years currently smoking or who had quit within the past month. Interviews included open-ended questions regarding prior experiences with digital health platforms and expectations and preferences for cessation treatment via various modalities (app-delivered, texting-based, or videoconferencing counseling). Interviews also elicited questions regarding digital modalities that integrated social components (app-delivered social forums and group videoconferencing counseling). Using an iterative, team-based approach, the thematic analysis identified meaningful themes. Interviews were supplemented with quantitative measures assessing sociodemographics, digital literacy, and physical health symptoms. Results: Participants (12/20, 60% men; 15/20, 75% White; 4/20, 20% Black or African American; 1/20, 5% Asian) were currently smoking (17/20, 85%) or had recently quit (3/20, 15%). Thematic analysis identified 3 meaningful themes across all digital modalities: convenience, accessibility, and personalization. Expected benefits of digital platforms included convenient treatment access, without reliance on transportation. Participants preferred treatments to be personalized and deliver content or strategies beyond standard education. Most (17/20, 85%) were unfamiliar with cessation apps but found them appealing given the potential for offering a novel quitting strategy. App ease of use (eg, easy navigation) was preferred. Half (10/20, 50%) would try a texting-based intervention, with many preferring texting with a counselor rather than automated messaging. Most (17/20, 85%) would use videoconferencing and expected this modality to deliver better quality counseling than via telephone. Expected videoconferencing challenges included looking presentable onscreen, technological difficulties, and privacy or security. Videoconferencing was regarded as the most personalized digital treatment, yet benefits unique to app-delivered and texting-based treatments included anonymity and access to treatment 24/7. Participants expected integrating social components into digital treatment to be useful for quit success and social connection, yet were concerned about possible interpersonal challenges. Conclusions: Because a long history of quit attempts and familiarity with standard quitting advice is common among older adults who smoke cigarettes, digital platforms might offer appealing and novel strategies for cessation that are accessible and convenient. Overall, this population was open to trying digital cessation treatments and would prefer that these platforms prioritize ease of use and personalized content. These findings challenge the bias that older adults are uninterested or unwilling to engage with digital treatments for behavioral health.
- 28 August 2024
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 26, e52919
Open AccessExpectations and Preferences for Digital Cessation Treatment: Multimethods Study Among Older Adults Who Smoke Cigarettes
Background: To address enduring age-related tobacco disparities, it is critical to promote cessation treatment among older adults (aged 65+ years). Digital health platforms offer opportunities for wide dissemination of evidence-based behavioral cessation support. However, existing digital cessation treatments are not tailored to unique aging-related needs and preferences, resulting in low uptake. Detailed information is needed about how to best adapt these treatments for this age group. Objective: We aimed to collect detailed, hypothesis-generating information about expectations and preferences for cessation digital treatment among older adults who smoke cigarettes. Methods: Semistructured interviews were conducted with adults aged 65+ years currently smoking or who had quit within the past month. Interviews included open-ended questions regarding prior experiences with digital health platforms and expectations and preferences for cessation treatment via various modalities (app-delivered, texting-based, or videoconferencing counseling). Interviews also elicited questions regarding digital modalities that integrated social components (app-delivered social forums and group videoconferencing counseling). Using an iterative, team-based approach, the thematic analysis identified meaningful themes. Interviews were supplemented with quantitative measures assessing sociodemographics, digital literacy, and physical health symptoms. Results: Participants (12/20, 60% men; 15/20, 75% White; 4/20, 20% Black or African American; 1/20, 5% Asian) were currently smoking (17/20, 85%) or had recently quit (3/20, 15%). Thematic analysis identified 3 meaningful themes across all digital modalities: convenience, accessibility, and personalization. Expected benefits of digital platforms included convenient treatment access, without reliance on transportation. Participants preferred treatments to be personalized and deliver content or strategies beyond standard education. Most (17/20, 85%) were unfamiliar with cessation apps but found them appealing given the potential for offering a novel quitting strategy. App ease of use (eg, easy navigation) was preferred. Half (10/20, 50%) would try a texting-based intervention, with many preferring texting with a counselor rather than automated messaging. Most (17/20, 85%) would use videoconferencing and expected this modality to deliver better quality counseling than via telephone. Expected videoconferencing challenges included looking presentable onscreen, technological difficulties, and privacy or security. Videoconferencing was regarded as the most personalized digital treatment, yet benefits unique to app-delivered and texting-based treatments included anonymity and access to treatment 24/7. Participants expected integrating social components into digital treatment to be useful for quit success and social connection, yet were concerned about possible interpersonal challenges. Conclusions: Because a long history of quit attempts and familiarity with standard quitting advice is common among older adults who smoke cigarettes, digital platforms might offer appealing and novel strategies for cessation that are accessible and convenient. Overall, this population was open to trying digital cessation treatments and would prefer that these platforms prioritize ease of use and personalized content. These findings challenge the bias that older adults are uninterested or unwilling to engage with digital treatments for behavioral health.
- 19 June 2024
- Published by Taylor & Francis in Substance Use & Misuse
- Vol. 59 (11) , 1620-1628
Individual Predictors of Response to A Behavioral Activation-Based Digital Smoking Cessation Intervention: A Machine Learning Approach
Background: Depression is prevalent among individuals who smoke cigarettes and increases risk for relapse. A previous clinical trial suggests that Goal2Quit, a behavioral activation-based smoking cessation mobile app, effectively increases smoking abstinence and reduces depressive symptoms. Objective: Secondary analyses were conducted on these trial data to identify predictors of success in depression-specific digitalized cessation interventions. Methods: Adult who smoked cigarettes (age = 38.4 ± 10.3, 53% women) were randomized to either use Goal2Quit for 12 weeks (N = 103), paired with a 2-week sample of nicotine replacement therapy (patch and lozenge) or to a Treatment-As-Usual (TAU) control (N = 47). The least absolute shrinkage and selection operator was utilized to identify a subset of baseline variables predicting either smoking or depression intervention outcomes. The retained predictors were then fitted via linear regression models to determine relations to each intervention outcome. Results: Relative to TAU, only individuals who spent significant time using Goal2Quit (56 ± 46 min) were more likely to reduce cigarette use by at least 50% after 12 weeks, whereas those who spent minimal time using Goal2Quit (10 ± 2 min) did not exhibit significant changes. An interaction between educational attainment and treatment group revealed that, as compared to TAU, only app users with an educational degree beyond high school exhibited significant reductions in depression. Conclusions: The findings highlight the importance of tailoring depression-specific digital cessation interventions to individuals' unique engagement needs and educational level. This study provides a potential methodological template for future research aimed at personalizing technology-based treatments for cigarette users with depressive symptoms.
- 19 June 2024
- Published by Taylor & Francis in Substance Use & Misuse
- Vol. 59 (11) , 1620-1628
Individual Predictors of Response to A Behavioral Activation-Based Digital Smoking Cessation Intervention: A Machine Learning Approach
Background: Depression is prevalent among individuals who smoke cigarettes and increases risk for relapse. A previous clinical trial suggests that Goal2Quit, a behavioral activation-based smoking cessation mobile app, effectively increases smoking abstinence and reduces depressive symptoms. Objective: Secondary analyses were conducted on these trial data to identify predictors of success in depression-specific digitalized cessation interventions. Methods: Adult who smoked cigarettes (age = 38.4 ± 10.3, 53% women) were randomized to either use Goal2Quit for 12 weeks (N = 103), paired with a 2-week sample of nicotine replacement therapy (patch and lozenge) or to a Treatment-As-Usual (TAU) control (N = 47). The least absolute shrinkage and selection operator was utilized to identify a subset of baseline variables predicting either smoking or depression intervention outcomes. The retained predictors were then fitted via linear regression models to determine relations to each intervention outcome. Results: Relative to TAU, only individuals who spent significant time using Goal2Quit (56 ± 46 min) were more likely to reduce cigarette use by at least 50% after 12 weeks, whereas those who spent minimal time using Goal2Quit (10 ± 2 min) did not exhibit significant changes. An interaction between educational attainment and treatment group revealed that, as compared to TAU, only app users with an educational degree beyond high school exhibited significant reductions in depression. Conclusions: The findings highlight the importance of tailoring depression-specific digital cessation interventions to individuals' unique engagement needs and educational level. This study provides a potential methodological template for future research aimed at personalizing technology-based treatments for cigarette users with depressive symptoms.
- Open Access
- 29 November 2023
- Published by Springer Nature in BMC Primary Care
- Vol. 24 (1) , 1-11
Rationale, design, and protocol for a hybrid type 1 effectiveness-implementation trial of a proactive smoking cessation electronic visit for scalable delivery via primary care: the E-STOP trial
Background: Cigarette smoking remains the leading cause of preventable disease and death in the United States. Primary care offers an ideal setting to reach adults who smoke cigarettes and improve uptake of evidence-based cessation treatment. Although U.S. Preventive Services Task Force Guidelines recommend the 5As model (Ask, Advise, Assess, Assist, Arrange) in primary care, there are many barriers to its implementation. Automated, comprehensive, and proactive tools are needed to overcome barriers. Our team developed and preliminarily evaluated a proactive electronic visit (e-visit) delivered via the Electronic Health Record patient portal to facilitate evidence-based smoking cessation treatment uptake in primary care, with promising initial feasibility and efficacy. This paper describes the rationale, design, and protocol for an ongoing Hybrid Type I effectiveness-implementation trial that will simultaneously assess effectiveness of the e-visit intervention for smoking cessation as well as implementation potential across diverse primary care settings. Methods: The primary aim of this remote five-year study is to examine the effectiveness of the e-visit intervention vs. treatment as usual (TAU) for smoking cessation via a clinic-randomized clinical trial. Adults who smoke cigarettes are recruited across 18 primary care clinics. Clinics are stratified based on their number of primary care providers and randomized 2:1 to either e-visit or TAU. An initial baseline e-visit gathers information about patient smoking history and motivation to quit, and a clinical decision support algorithm determines the best evidence-based cessation treatment to prescribe. E-visit recommendations are evaluated by a patient’s own provider, and a one-month follow-up e-visit assesses cessation progress. Main outcomes include: (1) cessation treatment utilization (medication, psychosocial cessation counseling), (2) reduction in cigarettes per day, and (3) biochemically verified 7-day point prevalence abstinence (PPA) at six-months. We hypothesize that patients randomized to the e-visit condition will have better cessation outcomes (vs. TAU). A secondary aim evaluates e-visit implementation potential at patient, provider, and organizational levels using a mixed-methods approach. Implementation outcomes include acceptability, adoption, fidelity, implementation cost, penetration, and sustainability. Discussion: This asynchronous, proactive e-visit intervention could provide substantial benefits for patients, providers, and primary care practices and has potential to widely improve reach of evidence-based cessation treatment. Trial registration: NCT05493254.
- 29 November 2023
- Published by Springer Nature in BMC Primary Care
- Vol. 24 (1) , 1-11
Open AccessRationale, design, and protocol for a hybrid type 1 effectiveness-implementation trial of a proactive smoking cessation electronic visit for scalable delivery via primary care: the E-STOP trial
Background: Cigarette smoking remains the leading cause of preventable disease and death in the United States. Primary care offers an ideal setting to reach adults who smoke cigarettes and improve uptake of evidence-based cessation treatment. Although U.S. Preventive Services Task Force Guidelines recommend the 5As model (Ask, Advise, Assess, Assist, Arrange) in primary care, there are many barriers to its implementation. Automated, comprehensive, and proactive tools are needed to overcome barriers. Our team developed and preliminarily evaluated a proactive electronic visit (e-visit) delivered via the Electronic Health Record patient portal to facilitate evidence-based smoking cessation treatment uptake in primary care, with promising initial feasibility and efficacy. This paper describes the rationale, design, and protocol for an ongoing Hybrid Type I effectiveness-implementation trial that will simultaneously assess effectiveness of the e-visit intervention for smoking cessation as well as implementation potential across diverse primary care settings. Methods: The primary aim of this remote five-year study is to examine the effectiveness of the e-visit intervention vs. treatment as usual (TAU) for smoking cessation via a clinic-randomized clinical trial. Adults who smoke cigarettes are recruited across 18 primary care clinics. Clinics are stratified based on their number of primary care providers and randomized 2:1 to either e-visit or TAU. An initial baseline e-visit gathers information about patient smoking history and motivation to quit, and a clinical decision support algorithm determines the best evidence-based cessation treatment to prescribe. E-visit recommendations are evaluated by a patient’s own provider, and a one-month follow-up e-visit assesses cessation progress. Main outcomes include: (1) cessation treatment utilization (medication, psychosocial cessation counseling), (2) reduction in cigarettes per day, and (3) biochemically verified 7-day point prevalence abstinence (PPA) at six-months. We hypothesize that patients randomized to the e-visit condition will have better cessation outcomes (vs. TAU). A secondary aim evaluates e-visit implementation potential at patient, provider, and organizational levels using a mixed-methods approach. Implementation outcomes include acceptability, adoption, fidelity, implementation cost, penetration, and sustainability. Discussion: This asynchronous, proactive e-visit intervention could provide substantial benefits for patients, providers, and primary care practices and has potential to widely improve reach of evidence-based cessation treatment. Trial registration: NCT05493254.
- 20 November 2023
- Published by Oxford University Press (OUP) in Nicotine & Tobacco Research
- Vol. 26 (6) , 696-703
Remote Carbon Monoxide Capture via REDCap: Evaluation of an Integrated Mobile Application
To improve the feasibility of remote biochemical verification of smoking status, our team developed “COast”, a mobile app integrated with REDCap that allows a research participant to complete self-report research assessments and provide a breath sample via the iCOQuit® Smokerlyzer® for the purposes of carbon monoxide (CO) testing. The aims of the present study were to examine: 1) the validity of remote CO data capture using COast as compared to gold standard approaches (salivary cotinine, stand-alone CO monitor) and 2) the feasibility of remote CO data capture using COast as applied to both daily and weekly CO collection schedules. Participants (N=143, 59% Female), including recently quit (n=36) and current (n=107) smokers, completed a baseline video session to capture validity data, and then were randomized to daily or weekly CO monitoring for a period of one month. Balancing both sensitivity and specificity, optimal cut-points for defining abstinence using the COast system were < 4 parts per million (ppm) with salivary cotinine as the referent (Sensitivity = 100%, Specificity = 92.8%) and < 8ppm with the stand-alone CO monitor as the referent (Sensitivity = 100%, Specificity = 88.9%). Compliance across groups with CO monitoring was high with average compliance of 74% for the daily group and 84% for the weekly group. Self-reported feasibility and acceptability of using the system were strong. Pairing the iCOQuit with REDCap via the COast app was both valid and feasible among a sample of adults who smoke cigarettes enrolled remotely. This integration may help to improve the rigor of decentralized smoking cessation trials. With increasing prevalence of decentralized trial designs, innovative methods are needed to remotely capture biomarkers. Methods that leverage existing widely available research data capture platforms may be particularly useful for promoting adoption. The COast app, which integrates a Bluetooth-enabled carbon monoxide monitor with REDCap, is a fitting, valid, feasible solution to remotely biochemically verify smoking status.
- 20 November 2023
- Published by Oxford University Press (OUP) in Nicotine & Tobacco Research
- Vol. 26 (6) , 696-703
Remote Carbon Monoxide Capture via REDCap: Evaluation of an Integrated Mobile Application
To improve the feasibility of remote biochemical verification of smoking status, our team developed “COast”, a mobile app integrated with REDCap that allows a research participant to complete self-report research assessments and provide a breath sample via the iCOQuit® Smokerlyzer® for the purposes of carbon monoxide (CO) testing. The aims of the present study were to examine: 1) the validity of remote CO data capture using COast as compared to gold standard approaches (salivary cotinine, stand-alone CO monitor) and 2) the feasibility of remote CO data capture using COast as applied to both daily and weekly CO collection schedules. Participants (N=143, 59% Female), including recently quit (n=36) and current (n=107) smokers, completed a baseline video session to capture validity data, and then were randomized to daily or weekly CO monitoring for a period of one month. Balancing both sensitivity and specificity, optimal cut-points for defining abstinence using the COast system were < 4 parts per million (ppm) with salivary cotinine as the referent (Sensitivity = 100%, Specificity = 92.8%) and < 8ppm with the stand-alone CO monitor as the referent (Sensitivity = 100%, Specificity = 88.9%). Compliance across groups with CO monitoring was high with average compliance of 74% for the daily group and 84% for the weekly group. Self-reported feasibility and acceptability of using the system were strong. Pairing the iCOQuit with REDCap via the COast app was both valid and feasible among a sample of adults who smoke cigarettes enrolled remotely. This integration may help to improve the rigor of decentralized smoking cessation trials. With increasing prevalence of decentralized trial designs, innovative methods are needed to remotely capture biomarkers. Methods that leverage existing widely available research data capture platforms may be particularly useful for promoting adoption. The COast app, which integrates a Bluetooth-enabled carbon monoxide monitor with REDCap, is a fitting, valid, feasible solution to remotely biochemically verify smoking status.
- Open Access
- 1 November 2023
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 25 (1) , e49809
Behavioral Activation–Based Digital Smoking Cessation Intervention for Individuals With Depressive Symptoms: Randomized Clinical Trial
Background: Depression is common among adults who smoke cigarettes. Existing depression-specific cessation interventions have limited reach and are unlikely to improve smoking prevalence rates among this large subgroup of smokers. Objective: This study aimed to determine whether a mobile app–based intervention tailored for depression paired with a mailed sample of nicotine replacement therapy (NRT) is efficacious for treating depression and promoting smoking cessation. Methods: A 2-arm nationwide remote randomized clinical trial was conducted in the United States. Adults (N=150) with elevated depressive symptoms (Patient Health Questionnaire-8≥10) who smoked were enrolled. The mobile app (“Goal2Quit”) provided behavioral strategies for treating depression and quitting smoking based on Behavioral Activation Treatment for Depression. Goal2Quit participants also received a 2-week sample of combination NRT. Treatment as usual participants received a self-help booklet for quitting smoking that was not tailored for depression. Primary end points included Goal2Quit usability, change in depression (Beck Depression Inventory-II) across 12 weeks, and smoking cessation including reduction in cigarettes per day, incidence of 24-hour quit attempts, floating abstinence, and 7-day point prevalence abstinence (PPA). Results: In total, 150 participants were enrolled between June 25, 2020, and February 23, 2022, of which 80 were female (53.3%) and the mean age was 38.4 (SD 10.3) years. At baseline, participants on average reported moderate depressive symptoms and smoked a mean of 14.7 (SD 7.5) cigarettes per day. Goal2Quit usability was strong with a mean usability rating on the System Usability Scale of 78.5 (SD 16.9), with 70% scoring above the ≥68 cutoff for above-average usability. Retention data for app use were generally strong immediately following trial enrollment and declined in subsequent weeks. Those who received Goal2Quit and the NRT sample reported lower mean depressive symptoms over the trial duration as compared to treatment as usual (difference of mean 3.72, SE 1.37 points less; P=.01). Across time points, all cessation outcomes favored Goal2Quit. Regarding abstinence, Goal2Quit participants reported significantly higher rates of 7-day PPA at weeks 4 (11% vs 0%; P=.02), 8 (7-day PPA: 12% vs 0%; P=.02), and 12 (16% vs 2%; P=.02). Conclusions: A mobile app intervention tailored for depression paired with a sample of NRT was effective for depression treatment and smoking cessation. Findings support the utility of this intervention approach for addressing the currently unmet public health treatment need for tailored, scalable depression-specific cessation treatments. Trial Registration: ClinicalTrials.gov NCT03837379; https://clinicaltrials.gov/ct2/show/NCT03837379
- 1 November 2023
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 25 (1) , e49809
Open AccessBehavioral Activation–Based Digital Smoking Cessation Intervention for Individuals With Depressive Symptoms: Randomized Clinical Trial
Background: Depression is common among adults who smoke cigarettes. Existing depression-specific cessation interventions have limited reach and are unlikely to improve smoking prevalence rates among this large subgroup of smokers. Objective: This study aimed to determine whether a mobile app–based intervention tailored for depression paired with a mailed sample of nicotine replacement therapy (NRT) is efficacious for treating depression and promoting smoking cessation. Methods: A 2-arm nationwide remote randomized clinical trial was conducted in the United States. Adults (N=150) with elevated depressive symptoms (Patient Health Questionnaire-8≥10) who smoked were enrolled. The mobile app (“Goal2Quit”) provided behavioral strategies for treating depression and quitting smoking based on Behavioral Activation Treatment for Depression. Goal2Quit participants also received a 2-week sample of combination NRT. Treatment as usual participants received a self-help booklet for quitting smoking that was not tailored for depression. Primary end points included Goal2Quit usability, change in depression (Beck Depression Inventory-II) across 12 weeks, and smoking cessation including reduction in cigarettes per day, incidence of 24-hour quit attempts, floating abstinence, and 7-day point prevalence abstinence (PPA). Results: In total, 150 participants were enrolled between June 25, 2020, and February 23, 2022, of which 80 were female (53.3%) and the mean age was 38.4 (SD 10.3) years. At baseline, participants on average reported moderate depressive symptoms and smoked a mean of 14.7 (SD 7.5) cigarettes per day. Goal2Quit usability was strong with a mean usability rating on the System Usability Scale of 78.5 (SD 16.9), with 70% scoring above the ≥68 cutoff for above-average usability. Retention data for app use were generally strong immediately following trial enrollment and declined in subsequent weeks. Those who received Goal2Quit and the NRT sample reported lower mean depressive symptoms over the trial duration as compared to treatment as usual (difference of mean 3.72, SE 1.37 points less; P=.01). Across time points, all cessation outcomes favored Goal2Quit. Regarding abstinence, Goal2Quit participants reported significantly higher rates of 7-day PPA at weeks 4 (11% vs 0%; P=.02), 8 (7-day PPA: 12% vs 0%; P=.02), and 12 (16% vs 2%; P=.02). Conclusions: A mobile app intervention tailored for depression paired with a sample of NRT was effective for depression treatment and smoking cessation. Findings support the utility of this intervention approach for addressing the currently unmet public health treatment need for tailored, scalable depression-specific cessation treatments. Trial Registration: ClinicalTrials.gov NCT03837379; https://clinicaltrials.gov/ct2/show/NCT03837379